Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2008Leukemia & lymphoma/Leukemia and lymphoma

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

View Full Paper
Ask AI
Bookmark
Share

Authors

SVSonia ValletUniversitätsklinikum KremsAPAntonio PalumboSemmelweis UniversityNRNoopur RajeBoston University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Vallet et al. (2008) studied this question.

synapsesocial.com/papers/69dd61830644c7b49d40d47fhttps://doi.org/10.1080/10428190802005191
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML)2006 · 54 citations
  2. 2Intracellular regulation of tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis in human multiple myeloma cells2002 · 153 citations
  3. 3Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines1999 · 873 citations
  4. 4Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring2006 · 212 citations
  5. 5Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients2007 · 102 citations